Panel Discussion - Refractory Equine Glandular Gastric Disease Morbidity and Mortality Case Discussions

Course overview

This interactive panel discussion brings together internationally recognised internal medicine specialists from Europe and the United States to discuss the challenges of treating Equine Glandular Gastric Disease EGGD and specifically how best to manage horses that are refractory to treatment. The discussion will focus primarily on pharmacological management but will also touch on other management and feeding strategies that can be used to improve healing rates and mitigate against reoccurrence. Whilst recognising the limitations surrounding availability of certain drug formulations in different countries, the panelists will debate what they consider to be first line and second line drugs for treatment of EGGD how they use them to maximise efficacy and how they would modify their approach in the case of a non responder. The panelists will contribute a wealth of clinical experience and anecdote to the discussion but will be encouraged to justify their approaches based upon current evidence where available. When do you consider a lesion healed How long should you wait before deciding a horse is a non-responder? Is there any value or science in determining intragastric pH in non-responders Should you biopsy lesions that are refractory to treatment? If so, how do you interpret the results What are the alternatives when acid suppression is not effective? When do you reach for corticosteroids Should competition horses be rested during treatment Are there any other management strategies that might be effective What is the role of the microbiome in horses with EGGD? Are antibiotics ever indicated Are there any nutritional risk factors that could potentially delay or prevent healing